Cytokinetics Files 8-K
Ticker: CYTK · Form: 8-K · Filed: May 28, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $51.00, $50.00, $500 million, $575 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-disclosure
TL;DR
Cytokinetics filed an 8-K, standard SEC update.
AI Summary
Cytokinetics, Inc. filed an 8-K on May 28, 2024, to report other events and financial statements. The filing does not contain specific details about new material events or financial results in the provided text, but it serves as a formal notification to the SEC.
Why It Matters
This filing is a routine corporate disclosure required by the SEC, indicating that Cytokinetics has made a regulatory filing regarding significant corporate events or financial updates.
Risk Assessment
Risk Level: low — This is a routine SEC filing and does not contain new material information that would inherently increase risk.
Key Players & Entities
- Cytokinetics, Inc. (company) — Registrant
- May 28, 2024 (date) — Date of Report
- 000-50633 (company) — Commission File Number
- 94-3291317 (company) — I.R.S. Employer Identification Number
- 280 East Grand Avenue, South San Francisco, California 94080 (location) — Address of Principal Executive Offices
- (650) 624-3000 (phone_number) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Cytokinetics, Inc.?
The 8-K filing is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
On what date was this 8-K filing reported?
The date of the report, and the date of the earliest event reported, is May 28, 2024.
What is Cytokinetics, Inc.'s principal executive office address?
Cytokinetics, Inc.'s principal executive offices are located at 280 East Grand Avenue, South San Francisco, California 94080.
What is Cytokinetics, Inc.'s telephone number?
Cytokinetics, Inc.'s telephone number, including area code, is (650) 624-3000.
What is Cytokinetics, Inc.'s Commission File Number?
Cytokinetics, Inc.'s Commission File Number is 000-50633.
Filing Stats: 960 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-05-28 16:01:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 CYTK The Nasdaq Stock Market LLC I
- $51.00 — price to the public in the offering was $51.00 per share of Common Stock. The Underwri
- $50.00 — he Underwriting Agreement at a price of $50.00 per share. Under the terms of the Under
- $500 million — ny from the offering were approximately $500 million before offering expenses payable by the
- $575 million — ny, or are expected to be approximately $575 million if the Underwriters exercise in full th
Filing Documents
- d811339d8k.htm (8-K) — 29KB
- d811339dex11.htm (EX-1.1) — 171KB
- d811339dex51.htm (EX-5.1) — 8KB
- g811339dsp46.jpg (GRAPHIC) — 4KB
- 0001193125-24-148077.txt ( ) — 382KB
- cytk-20240528.xsd (EX-101.SCH) — 3KB
- cytk-20240528_lab.xml (EX-101.LAB) — 17KB
- cytk-20240528_pre.xml (EX-101.PRE) — 11KB
- d811339d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 1.1 Underwriting Agreement, dated as of May 22, 2024, by and among Cytokinetics, Incorporated, J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: May 28, 2024 By: /s/ Sung Lee Sung Lee Executive Vice President, Chief Financial Officer